RxDoctor Payments Data

Timothy Klepper, MD

Family Medicine · Queenstown, MDNPI 1164684965

Payments from drug & device makers

$8,285in general payments, 2019–2025

Across 490 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Amgen$709
  • Lilly USA, LLC$592
  • AbbVie$527
  • AstraZeneca$526
  • Pfizer$474
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$8,285100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,285 in reported general payments places this provider in the 90th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$252,502
Medicare patients
640
Services billed
6,436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide81$115,439
OzempicSemaglutide76$87,181
EliquisApixaban71$84,793
XareltoRivaroxaban48$38,772
JanuviaSitagliptin Phosphate32$38,758
JardianceEmpagliflozin23$37,701
GemtesaVibegron19$25,270
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$22,744
MyrbetriqMirabegron23$17,255
FarxigaDapagliflozin Propanediol11$17,255
Tresiba Flextouch U-200Insulin Degludec14$16,734
Atorvastatin Calcium427$6,946
Breo ElliptaFluticasone/Vilanterol11$6,698
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$6,561
Dexlansoprazole DrDexlansoprazole15$5,273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$592$115,43981 claims
PfizerEliquis, Premarin$474$90,03084 claims
Novo NordiskOzempic$1,881$87,18176 claims
Johnson & JohnsonXarelto$72$38,77248 claims
MerckJanuvia$403$38,75832 claims
Boehringer IngelheimJardiance$232$37,70123 claims
GSKTrelegy Ellipta, Breo Ellipta$381$29,44241 claims
Sumitomo Pharma America, Inc.Gemtesa$93$25,27019 claims
Astellas Pharma US IncMyrbetriq$348$17,25523 claims
AstraZenecaFarxiga$526$17,25511 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$39$2,630250 claims
AbbVieSynthroid$527$1,73448 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Queenstown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →